turoctocog alfa pegol

Phase 3

Novo Nordisk A/S (NVO)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Congenital Bleeding Disorder

View Full Landscape

Drug Information

Target Indication

Congenital Bleeding Disorder

Clinical Trial

NCT02137850

Last updated: 12/11/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/20/2019

Esperoct

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Esperoct can be used for all age groups.

View on EMA

EMA11/13/2013

NovoEight

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Novoeight can be used for all age groups.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

NVO

Novo Nordisk A/S

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

CagrilintidePhase 3

Obesity or Overweight

NNC6019-0001Phase 3

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

biphasic insulin aspartPhase 3

Diabetes

Semaglutide 1.0 mgPhase 3

Obesity

ConcizumabPhase 3

Congenital Bleeding Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts